Investigation Initiated Against Supriya Lifescience Personnel Regarding Export Transaction
An investigation has been launched against Sreekant Sreedharan, General Manager of Sales & Marketing at Supriya Lifescience Ltd., by the Special Investigation and Intelligence branch of the Customs Department. The proceedings were initiated subsequent to an incident that occurred on July 3, 2026.The personnel is currently in judicial custody, which has been granted by the CMM court until July 17, 2026.
The investigation concerns procedures under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The charges relate to a procedural lapse pertaining to a single export transaction involving an identified product, as per details available with the company.
Supriya Lifescience Ltd. stated that it is closely monitoring the developments in this case. Based on the information currently available, the company assessed that these proceedings are not expected to have any material impact on its operations, financial position, or governance.
The company has initiated actions to evaluate the implications of the ongoing proceedings and is obtaining appropriate legal advice regarding the matter.
A summary of the investigation details is provided below:
| Particulars | Details |
|---|---|
| Name | Sreekant Sreedharan |
| Designation | General Manager, Sales & Marketing |
| Investigating Authority | Special Investigation and Intelligence branch of Customs Department |
| Date of Occurrence | July 3, 2026 |
| Nature of Proceedings | Procedures initiated under the NDPS Act, 1985 for a procedural lapse in a single export transaction. |
| Company Impact Assessment | Not expected to have any material impact on operations or financial position. |
SUPRIYA Stock Price Movement
Shares of Supriya Lifescience Limited slipped by 1.51%, settling on Friday at ₹978.9 after shedding ₹15.00 from the previous close. The stock traded with a volume of 193,627 shares in the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.